Download
Download by
Scanning QR Code
No matches yet
Please check network settings and try again Refresh
Loading
Futu Hot Stocks
    Latest News
    History record delete
      Quotes All >
      News All >
      Help All >

      • Download app

        Download app

      • Online Inquiry

        Log in to access Online Inquiry
      +
      Congratulations
      You've successfully got advanced quotes worth 5000 HKD
      Download APP >>
      Quotes
      Detailed Quotes
      Company Overview
      Company ProfileCompany Executives
      Financial Analysis
      Main CompositionKey IndicatorsFinancial Statement
      Multi-dimentional Analyses
      Company Valuation Capital Tracking Short Selling Data
      Futubull > Quotes > NTLA Intellia Therapeutics > Detailed Quotes

      NTLA Intellia Therapeutics

      Watchlist
      43.150
      +0.710+1.67%
      Close  02/01 16:00 ET
      43.350
      +0.200+0.46%
      Post Mkt Price 02/01 19:34 ET
      High
      43.730
      Open
      43.710
      Turnover
      51.44M
      Low
      40.900
      Pre Close
      42.440
      Volume
      1.21M
      Market Cap
      3.68B
      P/E(TTM)
      Loss
      52wk High
      104.870
      Shares
      85.23M
      P/E(Static)
      Loss
      52wk Low
      32.435
      Float Cap
      3.46B
      Bid/Ask %
      0.00%
      Historical High
      202.730
      Shs Float
      80.25M
      Volume Ratio
      1.05
      Historical Low
      9.180
      Dividend TTM
      --
      Div Yield TTM
      --
      P/B
      4.12
      Dividend LFY
      --
      Div Yield LFY
      --
      Turnover Ratio
      1.51%
      Amplitude
      6.67%
      Avg Price
      42.561
      Lot Size
      1
      Float Cap
      3.46B
      Bid/Ask %
      0.00%
      Historical High
      202.730
      Shs Float
      80.25M
      Volume Ratio
      1.05
      Historical Low
      9.180
      Dividend TTM
      --
      P/B
      4.12
      Dividend LFY
      --
      Turnover Ratio
      1.51%
      Amplitude
      6.67%
      Avg Price
      42.561
      Lot Size
      1
      Post-Market
      5D
      1D
      1W
      1M
      1Q
      1Y
      Price Forecast

      News

      Comment

      News

      Announcement

      Report

      Company Overview More
      Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
      CEO： Mr. John M. Leonard, M.D.
      Market： NASDAQ
      Listing Date： 05/06/2016
      Futu Hot List
      USHKCN
      TradeSearchNews
      SymbolLatest price%Chg

      Loading...

      Watchlist
      Back to the Top